Research progress of T cells in cholangiocarcinoma
Open accessThe DOI matches its Crossref record; 140 of the 141 references it cites were found in a registry or an index.
Abstract
Cholangiocarcinoma (CCA), a malignant tumor, is typically challenging to detect early and often results in a poor prognosis. In recent years, research interest has grown in the potential application of immunotherapy for CCA treatment. T cells, as a crucial component of the immune system, play a significant role in immune surveillance and therapy for cholangiocarcinoma. This article provides a review of the research advancements concerning T cells in cholangiocarcinoma patients, including their distribution, functional status, and correlation with patient prognosis within the tumor microenvironment. It further discusses the potential applications and challenges of immunotherapy strategies targeting T cells in CCA treatment and anticipates future research directions. A more profound understanding of T cells’ role in cholangiocarcinoma can guide the development of clinical treatment strategies, thereby enhancing patient survival rates and quality of life. Finally, we explored the potential risks and side effects of immunotherapy for T-cell cholangiocarcinoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Reduced T and B lymphocyte intrahepatic and increased tumor-associated intrahepatic and CD14+CD16+ circulating monocyte numbers are associated with poor survival in patients with intrahepatic cholangiocarcinoma [214–217].”
From Inflammation and immunity in liver homeostasis and disease: a nexus of hepatocytes, nonparenchymal cells and immune cells (2025) · doi:10.1038/s41423-025-01313-7 · cites this paper as [217]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
METABRIC Group, Curtis, C., Shah, S. P., Chin, S.-F., Turashvili, G., Rueda, O. M., Dunning, M. J., Speed, D., Lynch, A. G., Samarajiwa, S., et al. (2012) · Nature · doi:10.1038/nature10983 · Cited by 6,097
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Elements of cancer immunity and the cancer–immune set point
Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352 · cited 1×
“Thus, CCA must be considered an immune-rejecting tumor in which the majority of effector T cells are isolated at the tumor margin (64).”
Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
Chang, C.-H., Qiu, J., O’Sullivan, D., Buck, M. D., Noguchi, T., Curtis, J. D., Chen, Q., Gindin, M., Gubin, M. M., van der Windt, G. J. W., et al. (2015) · Cell · doi:10.1016/j.cell.2015.08.016 · Cited by 3,331
Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806 · cited 1×
“These include Cytokine Release Syndrome (CRS), characterized by elevated levels of in fl ammatory cytokines, particularly interleukin (IL)6, due to immune activation (130).”
Morgan, R. A., Yang, J. C., Kitano, M., Dudley, M. E., Laurencot, C. M., & Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.24 · Cited by 2,533
Miyara, M., Yoshioka, Y., Kitoh, A., Shima, T., Wing, K., Niwa, A., Parizot, C., Taflin, C., Heike, T., Valeyre, D., et al. (2009) · Immunity · doi:10.1016/j.immuni.2009.03.019 · Cited by 2,291
Joshi, N. S., Cui, W., Chandele, A., Lee, H. K., Urso, D. R., Hagman, J., Gapin, L., & Kaech, S. M. (2007) · Immunity · doi:10.1016/j.immuni.2007.07.010 · Cited by 1,861
Kaech, S. M., Tan, J. T., Wherry, E. J., Konieczny, B. T., Surh, C. D., & Ahmed, R. (2003) · Nature Immunology · doi:10.1038/ni1009 · Cited by 1,830
Razumilava, N., & Gores, G. J. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61903-0 · Cited by 1,729
T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition
Hui, E., Cheung, J., Zhu, J., Su, X., Taylor, M. J., Wallweber, H. A., Sasmal, D. K., Huang, J., Kim, J. M., Mellman, I., et al. (2017) · Science · doi:10.1126/science.aaf1292 · Cited by 1,689 · cited 1×
“PD-1 signaling further suppresses T cell function by speci fi cally inducing CD28 dephosphorylation (49).”
Wherry, E. J., Blattman, J. N., Murali-Krishna, K., van der Most, R., & Ahmed, R. (2003) · Journal of Virology · doi:10.1128/jvi.77.8.4911-4927.2003 · Cited by 1,610
Inhibitory B7-family molecules in the tumour microenvironment
Zou, W., & Chen, L. (2008) · Nature Reviews Immunology · doi:10.1038/nri2326 · Cited by 1,608
Kochenderfer, J. N., Dudley, M. E., Kassim, S. H., Somerville, R. P. T., Carpenter, R. O., Stetler-Stevenson, M., Yang, J. C., Phan, G. Q., Hughes, M. S., Sherry, R. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2025 · Cited by 1,595
Self-citationMittal, D., Gubin, M. M., Schreiber, R. D., & Smyth, M. J. (2014) · Current Opinion in Immunology · doi:10.1016/j.coi.2014.01.004 · Cited by 1,471
T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer
Tran, E., Robbins, P. F., Lu, Y.-C., Prickett, T. D., Gartner, J. J., Jia, L., Pasetto, A., Zheng, Z., Ray, S., Groh, E. M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609279 · Cited by 1,368
Brentjens, R. J., Rivière, I., Park, J. H., Davila, M. L., Wang, X., Stefanski, J., Taylor, C., Yeh, R., Bartido, S., Borquez-Ojeda, O., et al. (2011) · Blood · doi:10.1182/blood-2011-04-348540 · Cited by 1,286
Self-citationHuman T cell development, localization, and function throughout life
Kumar, B. V., Connors, T. J., & Farber, D. L. (2018) · Immunity · doi:10.1016/j.immuni.2018.01.007 · Cited by 1,257 · cited 1×
“After differentiating and maturing in the thymus, T lymphocytes are distributed to immune organs and tissues throughout the body, where they play a crucial role in immune responses through the circulation of lymphatic vessels, blood, and tissue fl uid (13).”
Foxp3 Reprograms T Cell Metabolism to Function in Low-Glucose, High-Lactate Environments
Angelin, A., Gil-de-Gómez, L., Dahiya, S., Jiao, J., Guo, L., Levine, M. H., Wang, Z., Quinn, W. J., Kopinski, P. K., Wang, L., et al. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2016.12.018 · Cited by 1,246
Self-citationMetabolic Regulation of T Lymphocytes
MacIver, N. J., Michalek, R. D., & Rathmell, J. C. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-095956 · Cited by 1,244
Kelley, R. K., Ueno, M., Yoo, C., Finn, R. S., Furuse, J., Ren, Z., Yau, T., Klümpen, H.-J., Chan, S. L., Ozaka, M., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00727-4 · Cited by 1,169
Tosolini, M., Kirilovsky, A., Mlecnik, B., Fredriksen, T., Mauger, S., Bindea, G., Berger, A., Bruneval, P., Fridman, W.-H., Pagès, F., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2907 · Cited by 1,146
Tissue-resident memory T cells: local specialists in immune defence
Mueller, S. N., & Mackay, L. K. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2015.3 · Cited by 1,006 · cited 1×
“In the tumor microenvironment (TME), epithelial cancer cells can express E-cadherin, interact with CD103 + CD8 + T cells, and maintain the interaction with cancer cells, leading to the residence of tumor antigen-reactive CD8 + T cells and a persistent anti-tumor effect in tumor tissues (52).”
Regulation of Cutaneous Malignancy by γδ T Cells
Girardi, M., Oppenheim, D. E., Steele, C. R., Lewis, J. M., Glusac, E., Filler, R., Hobby, P., Sutton, B., Tigelaar, R. E., & Hayday, A. C. (2001) · Science · doi:10.1126/science.1063916 · Cited by 1,004
CD28 Costimulation: From Mechanism to Therapy
Esensten, J. H., Helou, Y. A., Chopra, G., Weiss, A., & Bluestone, J. A. (2016) · Immunity · doi:10.1016/j.immuni.2016.04.020 · Cited by 937 · cited 1×
“CD28 signaling is compromised due to loss of competition with CTLA-4 for B7 family ligands (48).”
House, I. G., Savas, P., Lai, J., Chen, A. X. Y., Oliver, A. J., Teo, Z. L., Todd, K. L., Henderson, M. A., Giuffrida, L., Petley, E. V., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1868 · Cited by 790
Borger, D. R., Tanabe, K. K., Fan, K. C., Lopez, H. U., Fantin, V. R., Straley, K. S., Schenkein, D. P., Hezel, A. F., Ancukiewicz, M., Liebman, H. M., et al. (2012) · The Oncologist · doi:10.1634/theoncologist.2011-0386 · Cited by 728
Treg cell-based therapies: challenges and perspectives
Raffin, C., Vo, L. T., & Bluestone, J. A. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0232-6 · Cited by 720
Kaech, S. M., & Wherry, E. J. (2007) · Immunity · doi:10.1016/j.immuni.2007.08.007 · Cited by 625
Dynamics and specificities of T cells in cancer immunotherapy
Oliveira, G., & Wu, C. J. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-023-00560-y · Cited by 616
Kochenderfer, J. N., Dudley, M. E., Carpenter, R. O., Kassim, S. H., Rose, J. J., Telford, W. G., Hakim, F. T., Halverson, D. C., Fowler, D. H., Hardy, N. M., et al. (2013) · Blood · doi:10.1182/blood-2013-08-519413 · Cited by 590
Lowery, M. A., Ptashkin, R., Jordan, E., Berger, M. F., Zehir, A., Capanu, M., Kemeny, N. E., O'Reilly, E. M., El-Dika, I., Jarnagin, W. R., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0078 · Cited by 582
In Vivo CD4 + T Cell Differentiation and Function: Revisiting the Th1/Th2 Paradigm
Ruterbusch, M., Pruner, K. B., Shehata, L., & Pepper, M. (2020) · Annual Review of Immunology · doi:10.1146/annurev-immunol-103019-085803 · Cited by 550 · cited 1×
“…can be activated by the peptide-MHC class II complex on antigen-presenting cells (APCs), along with costimulatory signals and cytokine signaling, differentiating into several subsets characterized by distinct surface molecules and cytokine pro fi les, including Th1, Th2, Treg, Th17, etc (14, 15).”
An Eosinophil-Dependent Mechanism for the Antitumor Effect of Interleukin-4
Tepper, R. I., Coffman, R. L., & Leder, P. (1992) · Science · doi:10.1126/science.1636093 · Cited by 541
CD8+ T Cell Exhaustion in Cancer
Dolina, J. S., Van Braeckel-Budimir, N., Thomas, G. D., & Salek-Ardakani, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.715234 · Cited by 489
γδ T Cells Provide an Early Source of Interferon γ in Tumor Immunity
Gao, Y., Yang, W., Pan, M., Scully, E., Girardi, M., Augenlicht, L. H., Craft, J., & Yin, Z. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030584 · Cited by 453
Thommen, D. S., Schreiner, J., Müller, P., Herzig, P., Roller, A., Belousov, A., Umana, P., Pisa, P., Klein, C., Bacac, M., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0097 · Cited by 452
Bos, R., & Sherman, L. A. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1322 · Cited by 443
Induced Regulatory T Cells: Their Development, Stability, and Applications
Kanamori, M., Nakatsukasa, H., Okada, M., Lu, Q., & Yoshimura, A. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.08.012 · Cited by 442
γδ T cells: pleiotropic immune effectors with therapeutic potential in cancer
Silva-Santos, B., Mensurado, S., & Coffelt, S. B. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0153-5 · Cited by 425
Stevanović, S., Pasetto, A., Helman, S. R., Gartner, J. J., Prickett, T. D., Howie, B., Robins, H. S., Robbins, P. F., Klebanoff, C. A., Rosenberg, S. A., et al. (2017) · Science · doi:10.1126/science.aak9510 · Cited by 383
An osteopontin/CD44 immune checkpoint controls CD8+ T cell activation and tumor immune evasion
Klement, J. D., Paschall, A. V., Redd, P. S., Ibrahim, M. L., Lu, C., Yang, D., Celis, E., Abrams, S. I., Ozato, K., & Liu, K. (2018) · Journal of Clinical Investigation · doi:10.1172/jci123360 · Cited by 368
Spatial Heterogeneity in the Tumor Microenvironment
Yuan, Y. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026583 · Cited by 342
Biological Role and Therapeutic Potential of IDH Mutations in Cancer
Waitkus, M. S., Diplas, B. H., & Yan, H. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.04.011 · Cited by 335
Kurachi, M. (2019) · Seminars in Immunopathology · doi:10.1007/s00281-019-00744-5 · Cited by 314
Plasticity of Human CD4 T Cell Subsets
Geginat, J., Paroni, M., Maglie, S., Alfen, J. S., Kastirr, I., Gruarin, P., De Simone, M., Pagani, M., & Abrignani, S. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00630 · Cited by 292
Regulatory T Cells: Differentiation and Function
Plitas, G., & Rudensky, A. Y. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0193 · Cited by 282
Topography of cancer-associated immune cells in human solid tumors
Kather, J. N., Suarez-Carmona, M., Charoentong, P., Weis, C.-A., Hirsch, D., Bankhead, P., Horning, M., Ferber, D., Kel, I., Herpel, E., et al. (2018) · eLife · doi:10.7554/elife.36967 · Cited by 280
Clinical responses with T lymphocytes targeting malignancy-associated κ light chains
Ramos, C. A., Savoldo, B., Torrano, V., Ballard, B., Zhang, H., Dakhova, O., Liu, E., Carrum, G., Kamble, R. T., Gee, A. P., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci86000 · Cited by 276
Rizzo, A., Ricci, A. D., & Brandi, G. (2021) · Cancers · doi:10.3390/cancers13030558 · Cited by 259
Kansy, B. A., Concha-Benavente, F., Srivastava, R. M., Jie, H.-B., Shayan, G., Lei, Y., Moskovitz, J., Moy, J., Li, J., Brandau, S., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3167 · Cited by 246
Feng, K.-C., Guo, Y.-L., Liu, Y., Dai, H.-R., Wang, Y., Lv, H.-Y., Huang, J.-H., Yang, Q.-M., & Han, W.-D. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0378-7 · Cited by 243
Self-citationAlmeida, A. R., Correia, D. V., Fernandes-Platzgummer, A., da Silva, C. L., da Silva, M. G., Anjos, D. R., & Silva-Santos, B. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0597 · Cited by 229
Mapping spatial heterogeneity in the tumor microenvironment: a new era for digital pathology
Heindl, A., Nawaz, S., & Yuan, Y. (2015) · Laboratory Investigation · doi:10.1038/labinvest.2014.155 · Cited by 216
Polarized immune responses differentially regulate cancer development
Johansson, M., DeNardo, D. G., & Coussens, L. M. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00600.x · Cited by 209
Gamma Delta T-Cell Based Cancer Immunotherapy: Past-Present-Future
Saura-Esteller, J., de Jong, M., King, L. A., Ensing, E., Winograd, B., de Gruijl, T. D., Parren, P. W. H. I., & van der Vliet, H. J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.915837 · Cited by 195
Mann, G. J., Pupo, G. M., Campain, A. E., Carter, C. D., Schramm, S.-J., Pianova, S., Gerega, S. K., De Silva, C., Lai, K., Wilmott, J. S., et al. (2013) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.283 · Cited by 183
Inducible Expression of B7-H1 (PD-L1) and Its Selective Role in Tumor Site Immune Modulation
Sanmamed, M. F., & Chen, L. (2014) · The Cancer Journal · doi:10.1097/ppo.0000000000000061 · Cited by 178
Connecting blood and intratumoral Treg cell activity in predicting future relapse in breast cancer
Wang, L., Simons, D. L., Lu, X., Tu, T. Y., Solomon, S., Wang, R., Rosario, A., Avalos, C., Schmolze, D., Yim, J., et al. (2019) · Nature Immunology · doi:10.1038/s41590-019-0429-7 · Cited by 174
Ascierto, M. L., Kmieciak, M., Idowu, M. O., Manjili, R., Zhao, Y., Grimes, M., Dumur, C., Wang, E., Ramakrishnan, V., Wang, X.-Y., et al. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1470-x · Cited by 167
Self-citationDai, H., Zhang, W., Li, X., Han, Q., Guo, Y., Zhang, Y., Wang, Y., Wang, C., Shi, F., Zhang, Y., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1027469 · Cited by 166
Self-citationThe Emerging Epigenetic Role of CD8+T Cells in Autoimmune Diseases: A Systematic Review
Deng, Q., Luo, Y., Chang, C., Wu, H., Ding, Y., & Xiao, R. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00856 · Cited by 160
Wu, M.-J., Shi, L., Dubrot, J., Merritt, J., Vijay, V., Wei, T.-Y., Kessler, E., Olander, K. E., Adil, R., Pankaj, A., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1077 · Cited by 155
Tumour-infiltrating inflammatory and immune cells in patients with extrahepatic cholangiocarcinoma
Kitano, Y., Okabe, H., Yamashita, Y.-I., Nakagawa, S., Saito, Y., Umezaki, N., Tsukamoto, M., Yamao, T., Yamamura, K., Arima, K., et al. (2018) · British Journal of Cancer · doi:10.1038/bjc.2017.401 · Cited by 144
Alnaggar, M., Xu, Y., Li, J., He, J., Chen, J., Li, M., Wu, Q., Li, L., Liang, Y., Wang, X., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0501-8 · Cited by 142
Self-citationLorvik, K. B., Hammarström, C. L., Fauskanger, M., Haabeth, O. A. W., Zangani, M., Haraldsen, G., Bogen, B., & Corthay, A. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-1219 · Cited by 140
The role of tumor-infiltrating lymphocytes in cholangiocarcinoma
Liu, D., Heij, L. R., Czigány, Z., Dahl, E., Lang, S. A., Ulmer, T. F., Luedde, T., Neumann, U. P., & Bednarsch, J. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02340-2 · Cited by 134
Alvisi, G., Termanini, A., Soldani, C., Portale, F., Carriero, R., Pilipow, K., Costa, G., Polidoro, M. A., Franceschini, B., Malenica, I., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.05.043 · Cited by 121
Laheurte, C., Dosset, M., Vernerey, D., Boullerot, L., Gaugler, B., Gravelin, E., Kaulek, V., Jacquin, M., Cuche, L., Eberst, G., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0531-5 · Cited by 115
Current status of liver transplantation for cholangiocarcinoma
Goldaracena, N., Gorgen, A., & Sapisochín, G. (2017) · Liver Transplantation · doi:10.1002/lt.24955 · Cited by 110
The Ambiguous Role of γδ T Lymphocytes in Antitumor Immunity
Chitadze, G., Oberg, H., Wesch, D., & Kabelitz, D. (2017) · Trends in Immunology · doi:10.1016/j.it.2017.06.004 · Cited by 98
Lazarski, C. A., Ford, J. W., Katzman, S. D., Rosenberg, A. F., & Fowell, D. J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071949 · Cited by 93
CD4+ T helper 2 cells suppress breast cancer by inducing terminal differentiation
Boieri, M., Malishkevich, A., Guennoun, R., Marchese, E., Kroon, S., Trerice, K. E., Awad, M. E., Park, J. H., Iyer, S., Kreuzer, J., et al. (2022) · The Journal of Experimental Medicine · doi:10.1084/jem.20201963 · Cited by 91
Advances on chimeric antigen receptor-modified T-cell therapy for oncotherapy
Pang, Y., Hou, X., Yang, C., Liu, Y., & Jiang, G. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0840-y · Cited by 90
Xia, T., Li, K., Niu, N., Shao, Y., Ding, D., Thomas, D. L., Hao, J., Fujiwara, K., Hu, H., Osipov, A., et al. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01253-z · Cited by 84
Exhaust the exhausters: Targeting regulatory T cells in the tumor microenvironment
McRitchie, B., & Akkaya, B. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.940052 · Cited by 83
Anti-mucin 1 chimeric antigen receptor T cells for adoptive T cell therapy of cholangiocarcinoma
Supimon, K., Sangsuwannukul, T., Sujjitjoon, J., Phanthaphol, N., Chieochansin, T., Poungvarin, N., Wongkham, S., Junking, M., & Yenchitsomanus, P. (2021) · Scientific Reports · doi:10.1038/s41598-021-85747-9 · Cited by 79
The deleterious interplay between tumor epithelia and stroma in cholangiocarcinoma
Cadamuro, M., Stecca, T., Brivio, S., Mariotti, V., Fiorotto, R., Spirli, C., Strazzabosco, M., & Fabris, L. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.07.028 · Cited by 76
Interferons Induce CXCR3-cognate Chemokine Production by Human Metastatic Melanoma
Dengel, L. T., Norrod, A. G., Gregory, B. L., Clancy‐Thompson, E., Burdick, M. D., Strieter, R. M., Slingluff, C. L., & Mullins, D. W. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181fb045d · Cited by 71
Cholangiocarcinomas express fas ligand and disable the fas receptor
Que, F. G., Phan, V., Phan, V. H., Celli, A., Batts, K. P., LaRusso, N. F., & Gores, G. J. (1999) · Hepatology · doi:10.1002/hep.510300618 · Cited by 69
Diagnosis of Cholangiocarcinoma
Shin, D. W., Moon, S., & Kim, J. H. (2023) · Diagnostics · doi:10.3390/diagnostics13020233 · Cited by 68
Cholangiocarcinoma: risk factors, environmental influences and oncogenesis.
Al-Bahrani, R., Abuetabh, Y., Zeitouni, N., & Sergi, C. M. (2013) · PubMed · Cited by 66
Dual Face of Vγ9Vδ2-T Cells in Tumor Immunology: Anti- versus Pro-Tumoral Activities
Xiang, Z., & Tu, W. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01041 · Cited by 65
Penaloza‐MacMaster, P., Rasheed, A. U., Iyer, S. S., Yagita∥, H., Blazar, B. R., & Ahmed, R. (2011) · Journal of Virology · doi:10.1128/jvi.02205-10 · Cited by 64
Cheng, M., Liang, G., Zongyi, Y., Lin, X., Sun, Q., & Liu, Y. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04498-w · Cited by 63
PD-1/PD-L1 expression profiles within intrahepatic cholangiocarcinoma predict clinical outcome
Tian, L., Ma, J., Ma, L., Zheng, B., Liu, L., Song, D., Wang, Y., Zhang, Z., Gao, Q., Song, K., et al. (2020) · World Journal of Surgical Oncology · doi:10.1186/s12957-020-02082-5 · Cited by 58
Self-citationChen, L., Sun, R., Xu, J., Zhai, W., Zhang, D., Yang, M., Yue, C., Chen, Y., Li, S., Turnquist, H. R., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-1024 · Cited by 57
The immune milieu of cholangiocarcinoma: From molecular pathogenesis to precision medicine
Rimassa, L., Personeni, N., Aghemo, A., & Lleò, A. (2019) · Journal of Autoimmunity · doi:10.1016/j.jaut.2019.03.007 · Cited by 56
Qiao, Y., Chen, J., Wang, X., Yan, S., Tan, J., Xia, B., Chen, Y., Lin, K., Zou, F., Liu, B., et al. (2023) · 癌症:英文版 · doi:10.1002/cac2.12452 · Cited by 56
Self-citationSangsuwannukul, T., Supimon, K., Sujjitjoon, J., Phanthaphol, N., Chieochansin, T., Poungvarin, N., Wongkham, S., Junking, M., & Yenchitsomanus, P. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.107069 · Cited by 54
Cao, H., Huang, T., Dai, M., Kong, X., Liu, H., Zheng, Z., Sun, G., Sun, G., Rong, D., Jin, Z., et al. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.73949 · Cited by 54
Leffers, N., Fehrmann, R. S. N., Gooden, M. J. M., Schulze, U., ten Hoor, K. A., Hollema, H., Boezen, H. M., Daemen, T., de Jong, S., Nijman, H. W., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605820 · Cited by 53
FOXP3 Is a HCC suppressor gene and Acts through regulating the TGF-β/Smad2/3 signaling pathway
Shi, J.-Y., Ma, L., Zhang, J., Duan, M., Ding, Z., Yang, L., Cao, Y., Zhou, J., Fan, J., Zhang, X., et al. (2017) · BMC Cancer · doi:10.1186/s12885-017-3633-6 · Cited by 53
Self-citationChimeric Antigen Receptor T Cells Targeting Integrin αvβ6 Expressed on Cholangiocarcinoma Cells
Phanthaphol, N., Somboonpatarakun, C., Suwanchiwasiri, K., Chieochansin, T., Sujjitjoon, J., Wongkham, S., Maher, J. F., Junking, M., & Yenchitsomanus, P. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.657868 · Cited by 52
Kim, H., Jeong, S., Park, S., Lee, Y. J., Ju, Y. S., Kim, D., Song, G., Lee, J. H., Kim, S., Shin, J., et al. (2021) · Liver International · doi:10.1111/liv.14814 · Cited by 51
Expression of Th1- Th2- and Th17-associated cytokines in laryngeal carcinoma
Xu, X., Wang, R., Su, Q., Huang, H., Zhou, P., Luan, J., Liu, J., Wang, J., & Chen, X. (2016) · Oncology Letters · doi:10.3892/ol.2016.4854 · Cited by 46
Martin, S. D., Wick, D. A., Nielsen, J. S., Gierc, N. S., Holt, R. A., & Nelson, B. H. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1371895 · Cited by 45
How the matrix metalloproteinase MMP14 contributes to the progression of colorectal cancer
Claesson, L. (2020) · Journal of Clinical Investigation · doi:10.1172/jci135239 · Cited by 42
A Comparison of Prognostic Schemes for Perihilar Cholangiocarcinoma
Buettner, S., van Vugt, J. L. A., Gani, F., Koerkamp, B. G., Margonis, G. A., Ethun, C. G., Poultsides, G. A., Tran, T. B., Idrees, K., Isom, C. A., et al. (2016) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-016-3203-2 · Cited by 41
Autoimmunity affecting the biliary tract fuels the immunosurveillance of cholangiocarcinoma
Paillet, J., Plantureux, C., Lévesque, S., Le Naour, J., Stoll, G., Sauvat, A., Caudana, P., Tosello Boari, J., Bloy, N., Lachkar, S., et al. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20200853 · Cited by 41 · cited 1×
“By FigDraw. tumor-draining lymph nodes, and concentrated in CCA tissues compared with PSC mice or mice without cholangitis (66).”
Zimmer, C. L., Filipovic, I., Cornillet, M., O’Rourke, C. J., Berglin, L., Jansson, H., Sun, D., Strauss, O., Hertwig, L., Johansson, H., et al. (2021) · Hepatology · doi:10.1002/hep.32222 · Cited by 41
Carnevale, G., Carpino, G., Cardinale, V., Pisciotta, A., Riccio, M., Bertoni, L., Gibellini, L., Biasi, S. D., Nevi, L., Costantini, D., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-14838-3 · Cited by 40
Wathikthinnakon, M., Luangwattananun, P., Sawasdee, N., Chiawpanit, C., Lee, V. S., Nimmanpipug, P., Tragoolpua, Y., Rotarayanont, S., Sangsuwannukul, T., Phanthaphol, N., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-09964-6 · Cited by 40
Integrin αE(CD103)β7 in Epithelial Cancer
Hoffmann, J. C., & Schön, M. P. (2021) · Cancers · doi:10.3390/cancers13246211 · Cited by 36
Konishi, D., Umeda, Y., Yoshida, K., Shigeyasu, K., Yano, S., Toji, T., Takeda, S., Yoshida, R., Yasui, K., Fuji, T., et al. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01838-y · Cited by 36
Chen, L., Huang, H., Huang, Z., Chen, J., Liu, Y., Wu, Y., Li, A., Ge, J., Zhang, F., Xu, B., et al. (2023) · World Journal of Surgical Oncology · doi:10.1186/s12957-023-03009-6 · Cited by 36
Panya, A., Thepmalee, C., Sawasdee, N., Sujjitjoon, J., Phanthaphol, N., Junking, M., Wongkham, S., & Yenchitsomanus, P. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2212-2 · Cited by 35
Rodríguez-Tirado, C., Entenberg, D. R., Li, J., Qian, B., Condeelis, J. S., & Pollard, J. W. (2022) · Cancers · doi:10.3390/cancers14174336 · Cited by 35
Zhang, G., Ge, Z., Zhang, H., & Qiu, L. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110091 · Cited by 35
Prognostic role of tumoral PDL1 expression and peritumoral FoxP3+ lymphocytes in vulvar melanomas
Chłopik, A., Selim, M. A., Peng, Y. S., Wu, C.-L., Tell‐Martí, G., Paral, K. M., Shalin, S. C., Kraft, S., Hsu, C., Shea, C. R., et al. (2018) · Human Pathology · doi:10.1016/j.humpath.2017.12.022 · Cited by 28
Kim, H., Kim, J. H., Ryu, Y., Kim, D., Lee, S., Shin, J., Hong, S., Kim, K., Jung, D., Song, G., et al. (2020) · Cancer Research and Treatment · doi:10.4143/crt.2020.704 · Cited by 28
Junking, M., Grainok, J., Thepmalee, C., Wongkham, S., & Yenchitsomanus, P. (2017) · Tumor Biology · doi:10.1177/1010428317733367 · Cited by 27
Jiraviriyakul, A., Songjang, W., Kaewthet, P., Tanawatkitichai, P., Bayan, P., & Pongcharoen, S. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i29.3941 · Cited by 25
Mao, L., Su, S., Li, J., Yu, S., Gong, Y., Chen, C., Hu, Z., & Huang, X. (2023) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000460 · Cited by 25
Heij, L. R., Bednarsch, J., Tan, X., Rosin, M., Appinger, S., Reichel, K., Pecina, D., Doukas, M., van Dam, R. M., García-Vallejo, J. J., et al. (2023) · Cells · doi:10.3390/cells12060851 · Cited by 24
High level of CD73 predicts poor prognosis of intrahepatic cholangiocarcinoma
Xu, Y., Zhou, Y., Zhao, Y., Zhao, Y. F., Wang, F., Huang, X., & Guo, C.-Y. (2021) · Journal of Cancer · doi:10.7150/jca.51038 · Cited by 22
Self-citationSupimon, K., Sangsuwannukul, T., Sujjitjoon, J., Chieochansin, T., Junking, M., & Yenchitsomanus, P. (2022) · Cytotherapy · doi:10.1016/j.jcyt.2022.10.006 · Cited by 21
Wang, J., Loeuillard, E. J., Gores, G. J., & Ilyas, S. I. (2021) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2021.2010046 · Cited by 20
Zhang, Q.-W., Zhu, M., Liu, W., Rui, W., Chen, Y., Ding, X., Jiang, Y., Wu, Z., & Liu, B. (2024) · Translational Oncology · doi:10.1016/j.tranon.2024.101954 · Cited by 16
Sun, Q., Dong, X., Shang, Y., Sun, F., Niu, J., & Li, F. (2020) · Pathology - Research and Practice · doi:10.1016/j.prp.2020.153022 · Cited by 15
Wu, J., Guo, Y., Zuo, Z., Zhu, Z., & Han, L. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i19.2961 · Cited by 15
Advancing Cholangiocarcinoma Care: Insights and Innovations in T Cell Therapy
Dadgar, N., Arunachalam, A. K., Hong, H., Phoon, Y. P., Arpi-Palacios, J. E., Uysal, M., Wehrle, C. J., Aucejo, F., Ma, W. W., & Melenhorst, J. J. (2024) · Cancers · doi:10.3390/cancers16183232 · Cited by 15
Soejima, Y., Takeuchi, M., Akashi, T., Sawabe, M., & Fukusato, T. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041004 · Cited by 14
Zhang, Y., Chen, S., Li, J., Dai, W., & Qian, Y. (2021) · World Journal of Surgical Oncology · doi:10.1186/s12957-021-02168-8 · Cited by 14
Self-citationThe characteristics of the immune cell profiles in peripheral blood in cholangiocarcinoma patients
Kida, A., Mizukoshi, E., Kido, H., Toyama, T., Terashima, T., Arai, K., Yamashita, T., Fushimi, K., Yamashita, T., Sakai, Y., et al. (2021) · Hepatology International · doi:10.1007/s12072-021-10177-8 · Cited by 12
IDH1 Inhibition Reawakens the Immune Response against Cholangiocarcinoma
Zhu, Y., & Kwong, L. N. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1643 · Cited by 11
Human Vγ9Vδ2 T cell expansion and their cytotoxic responses against cholangiocarcinoma
Sawaisorn, P., Gaballa, A., Saimuang, K., Leepiyasakulchai, C., Lertjuthaporn, S., Hongeng, S., Uhlin, M., & Jangpatarapongsa, K. (2024) · Scientific Reports · doi:10.1038/s41598-024-51794-1 · Cited by 11
Suwanchiwasiri, K., Phanthaphol, N., Somboonpatarakun, C., Yuti, P., Sujjitjoon, J., Luangwattananun, P., Maher, J. F., Yenchitsomanus, P., & Junking, M. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116718 · Cited by 11
Panya, A., Thepmalee, C., Sawasdee, N., Saengmuang, S., Luangwattananun, P., & Yenchitsomanus, P. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115827 · Cited by 10
Immunotherapy: Pancreatic Cancer and Extrahepatic Biliary Tract Cancer
Perkhofer, L., Beutel, A. K., & Ettrich, T. J. (2019) · Visceral Medicine · doi:10.1159/000497291 · Cited by 9
Immunotherapy: balancing the risks and benefits
Oncology, T. L. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00028-7 · Cited by 9
High immune cell infiltration predicts improved survival in cholangiocarcinoma
Wirta, E., Szeto, S., Koppatz, H., Nordin, A. J., Mäkisalo, H., Arola, J. T., Sirén, J., Ahtiainen, M., Böhm, J., Mecklin, J., et al. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1333926 · Cited by 9
Mesenchymal stem cells: A novel treatment option for primary sclerosing cholangitis
Lightner, A. L., Dadgar, N., Vaidya, A. C., Simon, R., Fulmer, C. G., Siddiki, H. A., Menon, K. V., Liu, P., & Walsh, R. M. (2022) · Cell Biology International · doi:10.1002/cbin.11943 · Cited by 8
Ji, G., Xu, Q., Jiao, C., Lu, M., Xu, Z.-G., Zhang, B., Yang, Y., Wang, K., Li, X., & Wang, X. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2023.100839 · Cited by 8
Self-citationShi, H., Li, Z., & Zhu, M. (2024) · Current Medicinal Chemistry · doi:10.2174/0109298673296618240424095548 · Cited by 6
Zhou, Z., Zhang, Y., Xu, Z., Tang, X., Chen, X., Guan, J., & Zhang, Z. (2024) · Frontiers in Genetics · doi:10.3389/fgene.2023.1241834 · Cited by 5
Self-citation[The "Fas counterattack": a mechanism for immune evasion in human hilar cholangiocarcinomas].
Li, Z., Zhang, L., & Zou, S. (2002) · PubMed · Cited by 3
Research works printed but not linked: 1
- 86. Zheng Y Huang N Kuang S Zhang J Zhao H Wu J. The clinicopathological significance and relapse predictive role of tumor microenvironment of intrahepatic cholangiocarcinoma after radical surgery. Cancer. (2023) 129: 393– 404. doi: 10.1002/cncr.v129.3 36433731 PMC10099237 · doi:10.1002/cncr.v129.3
Cited by
(2025) · doi:10.1038/s41423-025-01313-7 · Cited by 97
Kong, L., & Piao, H. (2026) · Gastrointestinal Disorders · doi:10.3390/gidisord8030032
Metadata
- Authors
- Wang, Z., Dai, Y., Zhou, Y., Wang, Y., Chen, P., Li, Y., Zhang, Y., Wang, X., Hu, Y., Li, H., Li, G., & Jing, Y.
- Affiliations
- Shanxi Medical University (CN)
- Corresponding author
- Li, Gaopeng
- Jing, Yukai
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2025-02-25
- Volume
- 16
- Pages
- 1453344-1453344
- ISSN
- 1664-3224 (ISSN-L)
- PMC
- PMC11893616
- OpenAlex
- W4407929136
- Cited by
- 2
- References
- 141
- Citations by year
- 2026: 1 · 2025: 1
- FWCI
- 0.48
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Immunology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Cholangiocarcinoma and Gallbladder Cancer Studies
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Keywords
- cholangiocarcinoma, T cells, tumor microenvironment, cancer immunotherapy, T cell distribution, T cell function, prognosis, immune surveillance, immunotherapy side effects
- MeSH terms
- Animals, Bile Duct Neoplasms, Humans, Immunotherapy, Prognosis, T-Lymphocytes, Lymphocytes, Tumor-Infiltrating, Cholangiocarcinoma, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.